Castle Biosciences (CSTL) Assets Average (2019 - 2026)

Castle Biosciences has disclosed Assets Average across 8 years of filings, most recently posting $563.2 million for Q1 2026.

• Assets Average for Q1 2026 came in at $563.2 million, up 9.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $563.2 million (up 9.04% YoY), and the FY2025 annual result was $554.9 million, up 12.72% from the prior year.
• Assets Average came in at $563.2 million for Q1 2026 at Castle Biosciences, down from $570.7 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $570.7 million in Q4 2025 to a low of $426.1 million in Q2 2023.
• The 5-year median for Assets Average is $458.1 million (2022), against an average of $484.4 million.
• Across the five-year window, Assets Average decreased 5.98% in 2023 and increased 17.59% in 2024, its largest moves.
• Castle Biosciences' Assets Average stood at $452.6 million in 2022, then fell by 1.74% to $444.7 million in 2023, then advanced by 17.59% to $522.9 million in 2024, then grew by 9.14% to $570.7 million in 2025, then declined by 1.31% to $563.2 million in 2026.
• The last three Assets Average figures came in at $563.2 million (Q1 2026), $570.7 million (Q4 2025), and $553.8 million (Q3 2025), per Business Quant data.